The Food and Drug Administration (FDA) revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space. The two-pronged program is called Project Facilitate, run by the FDA Oncology Center of Excellence, and Expanded Access Navigator, which is operated by the Reagan-Udall Foundation for the FDA.…
People living with HIV can safely use checkpoint inhibitors, a type of immunotherapy that unleashes T-cell activity against cancer, according to study results presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. Researchers reported that the PD-1 checkpoint blocker Keytruda (pembrolizumab) and the PD-L1 blocker Imfinzi (durvalumab) were…
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab. During an ASCO presentation concurrent with release of a study in JAMA Oncology, Fred Hutch researcher and…
People with advanced colorectal cancer that has spread to the liver can undergo laparoscopic surgery instead of open surgery without affecting their chances of survival, according to data presented June 3 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Traditionally, when colorectal cancer metastasizes to the liver, surgeons perform open…
A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer (aNSCLC) available for enrollment, according to findings presented at the 2019 ASCO Annual Meeting. The study used enrollment criteria…
A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as proposed by ASCO and Friends of Cancer Research in 2017—would nearly double the percentage of patients eligible to enroll in clinical trials—from 52.3% to 98.5%. The…
It may be possible to double the number of patients eligible for clinical trials for advanced non–small-cell lung cancer (NSCLC). A study looking at 10,500 health records of advanced NSCLC patients has found that the use of expanded clinical trial inclusion criteria would nearly double the percentage of patients eligible to enroll in clinical trials,…
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enrol in clinical trials – from…
Dr R. Donald Harvey presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from a study looking at using ASCO’s CancerLinQ database to look expanding clinical trial inclusion criteria. Researchers looked at 10,500 health records of advanced non-small cell lung cancer and compared the traditional criteria with the proposed new…
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®. During an ASCO presentation concurrent with release of a…
